TNF and rheumatoid arthritis: Disease-modifying small molecule anti-rheumatic drugs (DMARDs) approved or under evaluation for therapy in RA include Janus kinase (JAK) inhibitors, TNF inhibitors, T cell co-stimulation blockers, IL-6 receptor inhibitors, promoters of B cell depletion, and interleukin 1 inhibitors.